ABSTRACT. Metabolic investigations, including the use of stable isotopes of calcium, were used to study calcium kinetics in three children with the hyperprostaglandin E syndrome. The studies were performed both during indomethacin treatment and in the absence of therapy. Off therapy, each child had hypercalciuria (mean urinary calcium excretion 0.478 mM/kg/d), hyperprostaglandinuria, and elevated serum calcitriol concentration. All had diminished bone density and were euparathyroid. Indomethacin treatment was associated with a marked reduction in serum calcitriol concentration, as well as decreased prostaglandin E excretion. Mean urinary calcium excretion fell to 0.135 mM/kg/d. The stable isotope studies defined two components to the hypercalciuria of this disease: an indomethacin-sensitive dietary contribution and a relatively indomethacin-resistant bone resorptive element. Bone densitometry confirmed the presence of the resorptive element by demonstrating skeletal demineralization. ( 
Bartter's syndrome, but differed in that the children demonstrated normal fractional distal chloride reabsorption and each had had a history of premature labor and polyhydramnios. Previously, a 6-y-old child diagnosed with severe idiopathic hypercalciuria had been described with features of the hyperprostaglandin E syndrome (4). Unlike the children reported by Seyberth et al., this child lacked evidence of an abnormality in potassium regulation. Although elevated plasma renin activity and aldosterone concentrations have been reported consistently in these patients, these findings are generally considered a consequence of renal prostaglandin synthesis, because they respond to therapy aimed at reducing this (3-1 1).
In children with these hyperprostaglandinuric syndromes, therapy with the cyclooxygenase inhibitor, indomethacin, favorably affects most of the clinical and the biochemical abnormalities (3-8, 12-19). In some patients with massive hypercalciuria and nephrocalcinosis, however, the reduction in the urinary calcium excretion by this therapy is incomplete (3, 5,6, 12, 13). The facts that marked hypercalciuria persists for years in these children despite maximal dosages of indomethacin, but not in others on therapy with similar degrees of nephrocalcinosis (20) , suggests that the hypercalciuria does not reflect dissolution of the calcinosis, but rather continued calcium excretion by established or alternative mechanisms. Such severe hypercalciuria places these children at risk of developing progressive nephrocalcinosis and renal failure (2 1, 22). To treat this disorder more effectively, it is necessary to understand the mechanisms mediating the excessive calcium loss.
A previous analysis of calcium balance, using 47Ca, concluded that three out of the four children with this disorder were in positive calcium balance (22) . This is in agreement with more recent studies that suggested excessive enteric calcium absorption contributed to the hypercalciuria (4, 6). Most reports, however, have implicated a primary renal reabsorptive defect (4, 22, 23). To investigate this problem further, we used a recently developed technique employing stable isotopes to measure calcium absorption and to determine the component of urinary calcium excretion derived directly from the diet. This was performed in three boys with massive hypercalciuria, hyperprostaglandinuria, and nephrocalcinosis, both on and off therapy with indomethacin.
MATERIALS AND METHODS
Patients. The patients are followed at Children's Hospital Medical Center, Cincinnati, OH, and State University of New York Health Sciences Center, Syracuse, NY. Each has polyuria, a urine concentrating defect, hypercalciuria, hyperprostaglandinuria, and nephrocalcinosis. The hypercalciuria partially but incompletely resolves with maximally tolerated dosages of in-domethacin. Patients 1 and 2 were included in a previous study from this laboratory, and their clinical features are detailed in that report (6). Patient 3 was recently investigated at age 4%2 y for polyuria, polydipsia, and nephrocalcinosis. During hypotonic saline diuresis, his fractional distal tubular chloride reabsorption, calculated at the moment of maximal free water clearance (24, 25), was 81%. He had a normal physical examination, plasma renin activity, and serum concentrations of electrolytes and aldosterone.
Three healthy children, ages 5.4 to 7.9 years, underwent the stable isotope protocol at USDA/ARS Children's Nutritional Research Center, Baylor College of Medicine, Houston, Texas. These children, who represent the age-matched control population for the stable isotope studies, had normal values for serum calcium, phosphate, albumin, creatinine, and alkaline phosphatase activity.
Informed consent was obtained from the parents of every child, and the investigational protocol was reviewed and approved by the respective institutional review boards.
Protocol. Sterile solutions of the chloride salts of 42Ca, 44Ca, and 46Ca were prepared by the National Institutes of Health pharmacy and tested for pyrogenicity and sterility before use. Calcium isotopes were obtained from Oak Ridge National Laboratory, Oak Ridge, TN.
Each patient was studied both off and on indomethacin. The drug was administered every 8 h at the largest dose tolerated without adverse gastrointestinal symptoms (range: 2.4-5.0 mg/ kg/d). Studies were performed in patient 3 prior to beginning indomethacin therapy; in the other patients, the initial studies were performed 72-96 h after the last dose of indomethacin. Our experience and that of others (3, 13, 26) suggest that this is an adequate washout period, since symptoms recurred in all patients, and it is consistent with the drug's t~,~ of 4-5 h. The children were given only water and indomethacin (when indicated) after the evening meal. 12.5 mM/kg of 44Ca was allowed to equilibrate in 8 ounces of milk overnight. After the first morning urine was collected, blood was drawn by venipuncture for measurement of iPTH and vitamin D metabolites, and 2.5 mM/kg 42Ca, diluted to 10 mL in half isotonic saline, was infused slowly. This was followed by breakfast, during which the isotopeequilibrated milk was drunk. The milk cartons were rinsed twice with water, and the the water was also drunk. Urine was collected for 24 h, and dietary assessment of 24-h calcium intake was performed from nursing and parental records by a staff dietitian. In the control subjects, an identical protocol was performed except that 46Ca was used as the oral tracer.
Analytical methods.
Aliquots from the 24-h urine collections were analyzed at the National Institutes of Health or at Baylor College of Medicine, where the enrichment of 42Ca and 44Ca (or 46Ca in control children) relative to 48Ca (43Ca in controls) was determined by thermal ionization mass spectrometry. This was used to calculate the fractional absorption of calcium and the fraction of each dose of isotope excreted in the urine (27) . These values allow the determination of Va and the component of the urinary Vou directly derived from the diet: Va = Vi x fractional absorption of calcium Vou = Vi x fraction of oral isotope excreted in urine Urine calcium concentration was measured by flame atomic absorption spectrophotometry and was used to determine Vu.
Vbu is the difference between Vou and Vu. For paired data, t test was used to analyze the response of these parameters to therapy.
Serum and urine electrolytes, calcium, phosphate, creatinine, and complete blood counts were measured in the clinical laboratory. Urine concentrations of cAMP and PGE2 were measured as previously described (6).
Vitamin D metabolites were extracted from serum by solidphase extraction cartridges, and the calcitriol concentration was measured by a competitive radioligand assay described previously (28). Coefficients of variance are 5.2% intraassay and 6.4% interassay.
Serum PTH concentration was determined by a two-site immunoradiometric assay (29) . This assay measures the intact PTH molecule and has a sensitivity of 1 pg/mL (0.1053 pmol/L). Intra-and interassay coefficients of variance are 4 and 8%, respectively (Allegro Intact PTH Immunoassay, Nichols Institute, San Juan Capistrano, CA).
Bone mineral content and bone width were determined by xray densitometry in patient 2 and by single-beam photon absorptiometry in patients 1 and 3. Measurements were taken from the left radius at the "midshaft" site, which is actually one-third the length between the ulnar styloid and the olecranon. These measurements were performed using a Hologic QDR-1000/W wholebody x-ray bone densitometer (Hologic Inc., Waltham, MA) in patient 2, and with a Lunar Bone Mineral Analyzer (Lunar Radiation Inc., Madison, WI) in patients 1 and 3. Bone mineral content:bone width ratios were compared with age, gender, and race-specific normal values (30) for the photon absorptiometry measurements and with an age-matched population of 13 normal children for the x-ray densitometry determinations (Bonny Specker, Ph.D., personal communication).
RESULTS

Calcium metabolism. Every patient was normocalcemic and
hypercalciuric (Vu >0.1 mM/kg/d) both off and on cyclooxygenase inhibitor therapy (Table 1) . Serum phosphate concentration was normal in patient 1 and mildly low in patient 3, whether or not indomethacin was taken. PTH concentrations were normal in each child not receiving indomethacin. Both phosphate and PTH concentrations were normal off therapy and slightly elevated during therapy in patient 2, probably because of renal insufficiency. Serum calcium concentrations decreased in each patient with therapy; ionized calcium concentrations were not obtained, but this was probably low in patient 2 during therapy, since his severe concentrating defect and alkalosis was refractory to indomethacin. Tmpo4/GFR was normal in patient 1 and reduced in patient 3; in neither child was the ratio appreciably affected by indomethacin. During therapy, this value rose to normal in patient 2. Urine cAMP was measured in patient 3 to assess renal PTH activity. The urine cAMP/creatinine ratios, off and on indomethacin respectively, were 10.3 and 9.3 nM/mg. The range of normal ratios, (2 SD below and above the mean) are 5.0-1 5.0 nM/mg. Serum concentrations of calcitriol were elevated in every child off indomethacin (Table 1) . These values returned to normal during therapy in patients 1 and 3; in patient 2, the calcitriol concentration decreased nearly 50% but remained slightly elevated. Similarly, each child off therapy was hyperprostaglandinuric, with PGE2 excretion exceeding the upper limit of 0.154 mM/h/1.73 m2 (2 SD above mean of normals) (6). Urine PGE2 excretion, as measured by PGE2/creatinine ratios, decreased with therapy in each patient, returning to normal in patients 1 and 2. Indomethacin was associated with a rise in the osmolality of the first morning urines and with a decrease in creatinine clearance in each child.
Except for patient 3, who had a calcium-rich diet, Vi was comparable with the age-matched controls (Table 2) . Va was increased to approximately twice the control value; whereas Vu, Vou, and Vbu were much more elevated in the patients than in the controls. Indomethacin was associated with an over 50% reduction in Vou in all ( p = 0.0 1 by paired t test), similar to the reduction in serum concentration of calcitriol. There was a less dramatic decline in Va and Vu with therapy. In contrast, the effect of therapy on Vbu was variable: in two patients, it decreased approximately 33%; in the other, it increased. The response of Va, Vu, and Vbu to therapy failed to achieve statistical significance. 
Bone density andgrowth. The BMC/BW ratio was low in each
The therapy of hypercalciuria in this disease has not been child, ranging from 67.6-84.5% of the mean values of control satisfactory. Diuretics (4, 5, 12, 22, 23), modification of dietary children (Table 3 ). In contrast, only the eldest boy was less than sodium (22) or calcium (3-5, 22), oral phosphate (22, 23), the fifth percentile in height. Patients 1 and 2 were each below prednisolone (3), and calcitonin have either been unsuccessful the fifth percentile when initially evaluated; the height of patient or associated with unacceptable complications. 3 was at the the 50th percentile. The linear growth velocities of Recognition of hyperprostaglandinuria in this syndrome led patients 1 and 2 increased from below the 3rd percentile during to attempts at treatment with cyclooxygenase inhibitors. Such the 6-mo interval preceding indomethacin therapy to above the treatment usually corrected polyuria and electrolyte disorders; 97th percentile during the initial 6 mo with this therapy. In its effect on calciuria, however, was less uniform (3-9, 12-14, contrast, there was no significant change in the growth velocity 33). Over the long term, hypercalciuria is associated with proof patient 3, which remained at approximately the 50th percent-gressive nephrocalcinosis and renal insuficiency. Thus, there is ile. Skeletal radiographs did not reveal rickets or hyperparathy-a critical need to establish an effective therapy. Before such roidism; either initially or after therapy with indomethacin had therapy can be designed, however, a better understanding of the been undertaken. mechanisms of hypercalciuria is clearly needed. We have used a new technique to quantitate the proportion of DISCUSSION urinary calcium excretion derived from recent diet and that
Royer et al. (3 1) were the first to report hypercalciuria in some which is tissue presumably bone. Our patients with chronic idiopathic hyperkaliuric hypokalemia, a previous suggestions us (6) and others (4, congenital disorder initially described by Rosenbaum 22) that enhanced enteric calcium absorption contributed to and Hughes (32). Several reports soon followed, confirming the h~~ercalciuria, and that this component was sensitive to indofindings of hypercalciuria and nephrocalcinosis in a subset of methacin therapy. The enhanced enteric absorption correlated these patients (5, 22, 23). previously, A~~~~ et (21) had with elevated serum concentrations of calcitriol, which also described two patients with a similar electrolyte disorder who decreased with cyclooxygenase inhibitor therapy. This is similar developed interstitial nephritis and terminal renal failure; ne-to a study in mhich either aspirin or indomethacin therapy p~roca~cinosis was evident in one patient, although urinary vou decreased calcitriol concentrations and reduced the incremental was never measured.
calciuric response to an oral calcium load (4). Although indomethacin therapy reduced both total (Vu) and can be excluded by our data.
* Numbers in parentheses are percentiles.
Increased serum concentrations of calcitriol may exert a calt Numbers in parentheses are percentages of mean BMC/BW in cium-mobilizing effect on bone. Although all patients had elematched, normal children.
vated serum calcitriol levels in the absence of treatment, these CALCIUM IN HYPERPROSTAGLANDIN E SYNDROME 9 5 values normalized on indomethacin. Despite a significant reduc-Also, we thank the families of both the patients and the control tion in the absorptive component of calcium excretion, massive children for their time and effort that was necessary to complete hypercalciuria persisted. these studies. Hyperparathyroidism is another potential cause of increased bone turnover in these children. Leonhardt 
